Puma Biotechnology, Inc. (PBYI)
9.83
-0.69
(-6.56%)
USD |
NASDAQ |
Oct 16, 16:00
9.83
0.00 (0.00%)
After-Hours: 20:00
Puma Biotechnology Research and Development Expense (Annual) : 62.07M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 62.07M |
| December 31, 2024 | 54.94M |
| December 31, 2023 | 50.38M |
| December 31, 2022 | 52.24M |
| December 31, 2021 | 71.87M |
| December 31, 2020 | 97.65M |
| December 31, 2019 | 132.85M |
| December 31, 2018 | 164.85M |
| Date | Value |
|---|---|
| December 31, 2017 | 207.81M |
| December 31, 2016 | 222.80M |
| December 31, 2015 | 208.47M |
| December 31, 2014 | 122.92M |
| December 31, 2013 | 45.05M |
| December 31, 2012 | 49.64M |
| December 31, 2011 | 0.8264M |
| December 31, 2010 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Anika Therapeutics, Inc. | 25.77M |
| Arcutis Biotherapeutics, Inc. | 77.05M |
| Olema Pharmaceuticals, Inc. | 157.70M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |